Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Pacira Biosciences Inc

PCRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$23.00

▼ -0.78%

Market Cap $916.82M · Vol 234.17K

Key Metrics

P/E Ratio

66.28

FWD: 6.93

Market Cap

$916.82M

Small Cap

Div Yield

N/A

EPS Growth

+9.73%

YoY

RSI (14)

31.00

Momentum

Beta

0.24

vs Market

52W High

$27.66

16.85% below

52W Low

$18.82

22.21% above

Volume

234.17K

Avg 240.19K

P/B

1.54

Price-to-book

ROE

16.62%

Return on equity

Free Float

98.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Pacira Biosciences Inc (PCRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.07%

-8.04%

-2.25%

+5.65%

YTD

-11.13%

-7.96%

-38.35%

-60.56%

Financials & Valuation

TTM · Annual

Total Revenue	$726.41M
Net Income	$7.03M
Revenue Growth (YoY)	+6.24%
Gross Margin	71.50%
Operating Margin	5.03%
Net Profit Margin	0.97%
ROE	16.62%
ROA · ROIC	1.20% · 1.08%

P/E Ratio	66.28
Forward P/E (FY1)	6.93
PEG Ratio	1.55
P/S	1.60
P/B	1.54
P/FCF	8.53
EPS Growth	+9.73%
Outstanding Shares	39.86M

Technical Indicators

50-Day SMA	$24.76
200-Day SMA	$23.61
RSI (14)	31.00
Beta	0.24
52-Week High	$27.66
52-Week Low	$18.82

Volume Today	234.17K
Avg Daily Volume (30D)	240.19K
Relative Volume	0.97x
Volatility (10D)	57.71
Volatility (30D)	39.08
Free Float	98.25%

Analyst Consensus

BUY

Current Price $23.00

Mean Target $30.00

52W Low$18.82 52W High$27.66

Current

Target

$18.82 $27.66

Current Analyst target

+30.43% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S77N12

ISINUS6951271005

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.